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Abstract
The superfamily of G protein-coupled receptors (GPCRs) consists of biological 
microprocessors that can activate multiple signaling pathways. Most GPCRs have 
an orthosteric pocket where the endogenous ligand(s) typically binds. Conversely, 
allosteric ligands bind to GPCRs at sites that are distinct from the orthosteric 
binding region and they modulate the response elicited by the endogenous ligand. 
Allosteric ligands can also switch the response of a GPCR after ligand binding to a 
unique signaling pathway, these ligands are termed biased allosteric modulators. 
Thus, the development of allosteric ligands opens new and multiple ways in which 
the signaling pathways of GPCRs can be manipulated for potential therapeutic 
benefit. Furthermore, the mechanisms by which allosteric ligands modulate the 
effects of endogenous ligands have provided new insights into the interactions 
between allosteric ligands and GPCRs. These new findings have a high potential 
to improve drug discovery and development and, therefore, creating the need for 
better screening methods for allosteric drugs to increase the chances of success in 
the development of allosteric modulators as lead clinical compounds.
Keywords: GPCRs, allosteric modulators, biased signaling, β-Arrestin, G-protein, 
orthosteric site, endogenous agonist
1. Introduction
Allosteric modulators are small molecules or peptides that by specifically inter-
acting with the receptor can alter the affinity, and/or efficacy of the endogenous 
hormone or other orthosteric ligands including antagonists, and possibly even 
constitutive signaling by GPCRs. By modifying these pharmacological parameters, 
allosteric modulators can exert multiple effects on the signaling of GPCRs. Positive 
Allosteric Modulators (PAMs) potentiate the signaling of the receptor by increasing 
the affinity and/or efficacy of the endogenous ligand or other administered ago-
nists. On the contrary, Negative Allosteric Modulators (NAMs) decrease the affinity 
and/or efficacy of the agonists. Biased Allosteric Modulators (BAMs) will direct the 
agonist response to a single signaling pathway [1, 2].
Before going deeper into pharmacological concepts, it is necessary to define fun-
damental parameters used to describe the activity of a ligand. Affinity refers to the 
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capacity of a ligand to bind to a receptor. The efficacy of a ligand, is the ability of a 
ligand to activate or amplify a response after binding to a receptor. Then Furchgott 
defined intrinsic efficacy as efficacy divided by the total receptor number, in hopes 
of defining a unique ligand-receptor value much like a ligand’s affinity [3]. Earlier, 
Ariens had introduced the term ‘intrinsic activity’ of a ligand to explain the behav-
ior of partial agonists [4]. Ariens proposed assigning the maximum response of 
the endogenous ligand a value of 1 or 100% and partial agonists were expressed as 
a fraction of this response. The discovery of inverse agonists, ligands that can shut 
down constitutive signaling by a GPCR expanded the scale from −1 to 1 (or − 100–
100%). A ligand that does not produce a cellular response (i.e., zero efficacy) when 
bound to the orthosteric site of the receptor is termed an antagonist [5].
The site to which endogenous agonists bind to is defined as the orthosteric site. 
Allosteric modulators do not bind to this site. They bind to other sites and are thus 
termed allosteric sites [6]. Upon binding, modulators generally stabilize a pre-
existing conformation or change the structural conformation of the receptor. This 
will often modulate the orthosteric site and can modify the effects of the agonists, 
or in theory, inverse agonists [1]. Allosteric modulators can also stabilize one of the 
multiple conformational states of the receptor [7].
Experimentally, allosteric modulation can be challenging because the allosteric 
modulators may affect the affinity and/or efficacy differently for each agonist (see 
agonist or probe dependence discussed below). For instance, different agonists that 
induce the same cellular response, after binding to the same receptor, can be dif-
ferentially modulated by the same allosteric modulator [1]. Furthermore, they are 
usually difficult to screen for because they do not produce an effect by themselves 
and may not displace radiolabeled ligands used in binding assays.
Drugs that target the orthosteric site of G protein-coupled receptors (GPCRs) 
are currently the most common therapeutic tools. Allosteric binding sites (e.g., 
sites elsewhere on the receptors) are less well-defined and, therefore, less exploited 
clinically. Diversity in location, mechanism, and specificity of allosteric ligands are 
characteristics giving them a great potential to extend the range of the ways that 
drugs can modulate GPCR signaling.
2. Advantages of allosteric modulators
Allosteric modulators with no intrinsic efficacy will usually only exert their 
effects in the presence of an endogenous agonist. Thus, they can selectively tune 
cellular responses in tissues where the endogenous agonist exerts its physiological 
or pathophysiological functions. As a result, temporal and spatial aspects of the 
endogenous agonist signaling can be chronically maintained or even corrected in 
pathological states. Also, the saturation of allosteric binding sites limits itself the 
action of the allosteric modulator and the effect on the function of the agonist. This 
excellent property of the agonist overcomes the overdosing of a drug, making the 
allosteric modulators much safer than classical drugs [8].
A great benefit of using allosteric ligands for therapeutic applications is their 
huge potential to achieve greater selectivity at subtypes of GPCRs [8]. This could 
be due to greater diversity in the amino acid sequence of the allosteric binding sites 
compared to the orthosteric binding pocket. Another possibility is via selective 
cooperativity between the allosteric and orthosteric binding sites at a given receptor 
subtype. In addition, in some GPCRs, where the orthosteric binding site is not clear 
or its structure is poorly defined, the allosteric binding site might be a good alterna-
tive to target with small molecules; this has been observed in receptors with long 
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peptidic ligands and is frequently found with the class B GPCRs (which are GPCRs 
characterized of having a long N-terminal extracellular domain). In general, the 
advantages of allosteric modulators apply regardless of the specific therapeutic area 
or the tissue where the receptor is being targeted.
2.1 The challenge of agonist dependence
Radioligand binding and functional assays have particular advantages when they 
are used to screen for allosteric modulators of GPCRs. Nevertheless, the extent and 
direction (that is positive or negative) of the interaction between the allosteric and 
orthosteric ligand for receptors with more than one endogenous ligand will depend 
on the orthosteric agonist interacting with the receptor; this phenomenon is known 
as probe or agonist dependence (Figure 1). Agonist dependence makes more com-
plex the identification and pharmacological characterization of allosteric modula-
tors. Particularly, the case of aplaviroc (an allosteric modulator for CC-chemokine 
receptor 5) showed no effect in the binding of CCL5 to the receptor but totally 
prevented the binding of CCL3 [9].
Agonist dependence, or better known as probe dependence, can seriously affect 
potential therapeutics and also the development of allosteric ligands. In the ideal 
situation, the endogenous ligand would be used as a prototypic ligand in the high 
throughput screening process during drug development. However, in a real situa-
tion, the endogenous agonists, most of the time are unsuitable and susceptible to 
rapid degradation along the drug screening process and even more during in vivo 
studies. For this reason, highly stable agonists are preferentially used. Therefore, 
the allosteric ligand is first tested with the natural ligand on an early stage of the 
process in order to conclude if the achieved effects are equivalent to those registered 
with the prototypical agonist.
In order to better illustrate this concept a good example would be when a PAM 
has the ability to increase the cholinergic neuronal transmission in Alzheimer’s dis-
ease [10], but the endogenous ligand acetylcholine is of rapid degradation making 
it unsuitable for drug screening. Cholinergic substitute ligands such as carbachol 
or pilocarpine are used for screening, and the stable analog oxotremorine is used 
to validate the effects of muscarinic acetylcholine receptor (mAChR) allosteric 
modulators in vivo [11]. However, the effects of the PAM LY2033298 are dependent 
on the orthosteric agonist (carbachol or pilocarpine) being used [12, 13] and these 
effects could lead to unexpected profiles of the allosteric ligand in later stages of the 
drug discovery process.
The characteristic of some allosteric ligands to have differential probe 
dependence on multiple receptor subtypes is an additional consideration that 
can have significant implications for the drug screening process. For instance, 
LY2033298 was reported to be a specific positive allosteric modulator of the 
M4 mAChR. Accordingly, PAM LY2033298 increased acetylcholine-mediated 
calcium responses at the M4 mAChR but not for the rest of the four receptor 
subtypes [14]. This allosteric modulator has also been shown to have high positive 
cooperativity with the surrogate orthosteric ligands oxotremorine and tetrameth-
ylammonium at the M2 mAChR [13]; this positive cooperative effect is similar 
to that observed with LY2033298 and oxotremorine at the M4 mAChR. This is 
an example of how the probe-dependent interaction of oxotremorine at both the 
M2 and M4 receptor subtypes can confound experimental interpretation of the 
effect of the allosteric ligand in vivo [11]. This highlights the need to understand 
the probe dependence of allosteric ligands at related receptors to ensure a robust 
target validation.
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Probe dependence is irrelevant in many physiological systems because the 
therapeutically targeted GPCRs have only one endogenous ligand. However, as we 
mentioned above, receptors can also respond to several endogenous agonists, under 
physiological conditions and disease. It is important to mention few more examples 
like the case of the chemokine receptors [15], melanocortin receptors [16], para-
thyroid hormone receptor 1 [17], relaxin receptors [18], calcium-sensing receptors 
[19], calcitonin and calcitonin-like receptors [20], as well as glucagon and glucagon-
like peptide 1 (GLP1) receptors [21] and galanin receptors. In these examples, 
agonist dependence represents a huge challenge in the development of allosteric 
ligands as well as their therapeutic application.
Figure 1. 
Agonist dependence and biased agonism. (A) Agonist dependence of an allosteric ligand is shown with several 
endogenous agonists. (Aa) An allosteric modulator potentiates the ability of endogenous Agonist-1 to inhibit the 
binding of an antagonist to a human GPCR. (Ab) An allosteric modulator displaying weak or almost neutral 
cooperativity with endogenous Agonist-2. (Ac) An allosteric modulator displaying neutral cooperativity 
with endogenous Agonist-3. (B) Biased agonism is the capacity of different agonists to differentially activate 
the same GPCR, producing specific sets of signaling pathways. Changes in efficacy or potency by different 
agonists are indicators of potential biased agonism for a given GPCR. (Ba) Allosteric modulator-A showing 
stronger potency for signaling-A than for signaling-B, and not showing effect at signaling-C. (Bb) Allosteric 
modulator-B displaying higher potency for signaling-B than for signaling-A. (Bc) A biased agonist in complex 
with a GPCR can by itself preferentially activate to a unique set of signaling pathways and the interaction of 
the ligand-GPCR complex with an allosteric ligand will affect the signaling bias of the GPCR. Ligand-C is 
co-bound with an allosteric modulator-A and it potentiates the stimulus towards pathway-B and generates 
activity on signaling-C, however it down regulates signaling-A. This can be observed by a change in potency 
and efficacy between signaling-B and signaling-C in comparison with signaling-A.
5Allosteric Modulators for GPCRs as a Therapeutic Alternative with High Potential in Drug…
DOI: http://dx.doi.org/10.5772/intechopen.91838
2.2 Biased agonism in allosteric modulation
Distinct ligands can show different capacities to differentially activate signaling 
pathways from a GPCR by inducing different structural conformations [8, 22]; this 
effect is termed as biased signaling (also known as biased agonism see Figure 2). 
Examples of ligands that produce biased signaling include classical orthosteric 
adrenoceptor antagonists and inverse agonists (also known as beta-blockers) that 
antagonize receptor-mediated cyclic AMP production but promote cAMP response 
element-mediated gene transcription [23].
Research of carvedilol, an adrenoceptor antagonist, has shown to be a superior 
therapeutic, as compared to other adrenoceptor antagonists, for heart failure 
therapy [24] Despite that the drug was shown to be an inverse agonist for Gαs 
dependent signaling, it was also observed that carvedilol exerts partial agonism 
inβ -arrestin-dependent extracellular signal-regulated kinase 1 (ERK1) and ERK2 
phosphorylation [25]. Based on these observations we can hypothesize that a 
different set of efficacies in different signaling pathways determines the final 
therapeutic outcome of GPCR ligands. Biased signaling has been widely studied 
for orthosteric ligands, however, there is also the possibility that many, if not all 
allosteric ligands, will exert biased signaling properties when the receptor is co-
bound to the agonist.
At the present time, the terms biased agonism and allosteric modulation are 
usually considered to be different pharmacological phenomena. However, both 
events share in common that they are due to ligand-specific conformational changes 
in the GPCR that implicates a change in the three-dimensional structure of the 
GPCR. Having as a result that some specific signaling pathways can be either 
positively or negatively regulated.
For instance, the allosteric modulators of parturition (PDC113.824) induce 
biased signaling when an orthosteric ligand is co-bound to the prostaglandin F2α 
receptor. In mouse models, this compound acts as a negative allosteric modulator of 
prostaglandin F2α receptor-mediated cytosolic calcium oscillations and myometrial 
contraction. Specifically, PDC113.824 uncouples the receptor from the Gα12–RHO–
ROCK (RHO-associated protein kinase) signaling pathway, but still significantly 
increases the phosphorylation of ERK1 and ERK2 Gαq dependent [26]. An auto-
antibody for the calcium-sensing receptor that produces acquired hypocalciuric 
hypercalcemia by selectively increasing Gαq-dependent signaling and inhibiting 
Figure 2. 
Biased agonism is the ability of a receptor-ligand complex to selectively activate its downstream signaling 
pathways. (a) A balanced signal that stimulates both signaling pathways, G-protein dependent or β-arrestin 
dependent, equally in the same manner. (b) A biased ligand acting on the receptor as an agonist of one 
pathway (e.g., β-arrestins) while acting as an antagonist of another pathway (e.g., through heterotrimeric G 
proteins). (c) A biased ligand acting on the receptor as an agonist of one pathway (e.g., through heterotrimeric 
G proteins) while acting as an antagonist of another pathway (e.g., beta-arrestins).
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Gαi-dependent signaling [27]. This is only one example of how an allosteric modu-
lator can induce biased signaling that results in disease.
Based on these examples is that we can see the need to deeply understand the 
effect of allosteric modulation at different signaling pathways, as positive and 
negative regulation of every pathway from the receptor, does not always generate a 
beneficial therapeutic effect.
In theory, the operational model describes that biased agonism via allosteric 
modulation is a pathway-dependent variation in the signaling produced by the 
agonist in such a way that is not correlated with the intrinsic efficacy of the agonist 
or allosteric modulators [28]. However, in real conditions, biased signaling by 
an allosteric modulator is when the allosteric ligand potentiates one pathway but 
decreases the other one, as we previously described.
For a better understanding of this pharmacological phenomenon, we can con-
tinue describing more examples in this regard. Another very good example is the case 
of the allosteric modulation of the muscarinic receptor M4 subtype (M4 mAChR). 
Increasing signaling at M4 mAChR by the allosteric modulator LY2033298 generated 
significant changes in the grade of positive cooperativity in various signaling cas-
cades of this receptor [29]. An additional case to exemplify this is the biased alloste-
ric modulation of the GLP1 receptor. Some allosteric ligands can potentiate cAMP 
production and having a smaller effect on β-arrestin dependent signaling [30, 31].
Currently, most allosteric modulators have been discovered following screening 
assays; such as those used to identify agonists and antagonists, instead of a thought-
ful rational process. The development of novel allosteric modulators that can induce 
biased agonism has the potential of specifically targeting therapeutic signaling 
pathways and excluding off-target pathways providing in this way a novel mecha-
nism of biased agonism and produce new drugs with fewer side effects. However, 
we also face the problem that poses a big challenge in drug discovery and develop-
ment of allosteric ligands and is that for the vast majority of GPCRs, it is still not 
well understood which set of signaling pathways efficacies will produce the desired 
therapeutic effect. The most important issue in the development of biased allosteric 
ligands is required a full understanding of the molecular determinants and also 
structural signatures that will lead to biased signaling on a receptor.
2.3 Agonist dependence in allosteric modulation and biased agonism
Many GPCRs have more than one endogenous agonist in such a way that their 
action is differentially regulated by the same allosteric modulator, having, as a result, 
a phenomenon called probe dependence. For instance, in the case of GLP1 receptor, 
there are two PAMs (compound 2 and BETP (4-(3-benzyloxyphenyl)-2-ethylsulfi-
nyl-6-(trifluoromethyl) pyrimidine)) that show agonist dependence; where they 
increased the affinity of the oxyntomodulin (an endogenous agonist) by 18–25 times 
respectively. In contrast, none of them had no effect on four more ligands of GLP1 
receptor [30, 32]. Interestingly, these allosteric modulators induced biased signaling 
during GLP-1 activation by oxyntomodulin. Observing an increase in Gαs activa-
tion, β-arrestin1/2 recruitment and insulin secretion, but they did not show any allo-
steric effect in ERK1/2 activation. The capacity of a modulator to regulate all or only 
some endogenous ligands in a pathway-dependent manner could not only seriously 
affect the development of novel allosteric modulators but also their therapeutics.
2.4 Implications in drug screening
Currently, allosteric screening routinely relies on seeking compounds that 
regulate the actions of the main endogenous ligand. Conversely, screening against 
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alternative endogenous ligands, even if they have lower affinity or efficacy, may 
yield new leads that might not be possible to identify if screening for cooperative 
effects is only performed using the main endogenous ligand.
The possibility that an allosteric modulator will antagonize or potentiate the 
effects of an endogenous agonist without affecting other endogenous agonists 
would be seen as a therapeutic advantage, only in the case that each agonist exerts 
a different physiological effect. For example, according to previous studies some 
CCR5 allosteric modulators prevent the interaction of HIV-1 to CCR5, inhibiting 
in this way the infection [33]. However, it has not been well understood, whether 
inhibiting the chemokine physiological function of CCR5, would be desirable from 
a therapeutic point of view. During AIDS treatment, it is highly desirable the avail-
ability of allosteric modulators that prevent the HIV-1 entry without affecting CCR5 
internalization by chemokines, since CCR5 plays a key role in favorable protection 
in the progression of AIDs after HIV-1 infection [34].
Probe dependent effects and the capacity of allosteric ligands to induce allosteric 
bias could be used to regulate GPCR physiological function in such a way that the 
signaling pathways that lead to favorable physiological outputs can be selectively 
targeted.
2.5 GPCR structure and allosteric modulation
All GPCRs are involved in nearly all physiological functions in humans and are 
the target of intense drug discovery efforts [35, 36]. Recent structures of GPCRs 
bound to allosteric modulators have revealed that the receptor surface is character-
ized by diverse cavities and crevices that may serve as binding sites for allosteric 
modulators [37]. This supports the notion that GPCRs are structurally flexible 
and they can be regulated by different allosteric ligands through a wide variety of 
mechanisms [38–43]. The vast majority of these structures have been solved with 
NAMs, which stabilize receptors in their inactive states [37]. Currently, only a single 
structure of an active GPCR bound to a small-molecule PAM has been described, 
the M2 muscarinic acetylcholine receptor with LY2119620 [44]. Thus, mechanisms 
of PAMs and their potential binding sites remain unexplored.
2.6 Therapeutic relevance
Receptor subtypes have orthosteric sites that are similar in its tridimensional 
structure and sometimes even in their amino acid sequence since mutations within 
this site, may especially decrease receptor function with detrimental consequences 
for the system. This can be harmful in complex systems and thus, evolution does 
not frequently favor such changes. In contrast, allosteric binding sites are less criti-
cal for receptor function and this is why they often have great structural variation 
between receptor subtypes. Moreover, in contrast to orthosteric ligands, allosteric 
drugs have the potential of being highly specific by only targeting a very specific set 
of receptor subtypes. But also, it is worth to highlight that the same allosteric site 
might be structurally different across species, having as a consequence differential 
effects of the same allosteric ligand between species [45].
Allosteric ligands cannot activate or inactivate receptors. Specifically, allo-
steric action will depend on endogenous ligands like neurotrophins, hormones, 
nucleotides or lipid moieties whose levels in the organism are tightly regulated. 
This can lower overdose risk relative to similarly acting orthosteric drugs. It may 
also allow a strategy where large enough doses that saturate all the receptors 
of the target tissue can be administrated to prolong the drug effect [5]. These 
characteristics enable receptors to be activated at specific times (i.e., in response 
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to a physiological stimulus) with the difference of the constant activation by an 
orthosteric agonist [45].
Allosteric ligands regulate the responses already existing within tissues and 
making possible the drug response on specific tissue. Contrary to orthosteric 
ligands where they produce a less targeted effect within the organism since they 
bind to every receptor they can, affecting multiple tissues expressing the target 
receptor [1].
Some allosteric modulators have also been shown to lack the desensitizing effect 
that some agonists. Nicotinic acetylcholine receptors, for example, quickly desensi-
tize in the presence of agonist drugs but maintain normal function in the presence 
of PAMs [46].
3. Conclusions
A huge number of drugs with fewer side effects are being developed using 
allosteric targets. Only two types of screening strategies are the principal approach 
in drug discovery; phage display and high-throughput screening. It is foreseen that 
complex computations will be conducted in years to come in order to gain better 
insights about the binding pockets within the receptors for which allosteric modula-
tors can potentially be designed [47–49]. Information from crystal structures of 
receptors bound to different ligands would provide structural insights about the 
conformational changes that occur upon ligand binding. These studies would be 
fundamental during a rational drug design of these kind of ligands. In the last few 
years, we have seen a great advance in the design of novel allosteric modulators and 
it will possibly intensify even more in the near future. Progress in drug delivery will 
help to obtain further spatial specificity of therapeutic drugs, and as a result, we 
expect will translate into identifying significantly increased number of new drug 
possibilities that are more effective and with fewer side effects [50, 51]. However, 
no matter how selective such drugs can be designed, they cannot equalize the 
spatiotemporal basis of specificity that occurs naturally in our systems. Therefore, 
every single advance in allosteric drug discovery that promotes the homeostasis of 
our biological systems, will significantly contribute to the goals of developing more 
effective drugs with fewer side effects.
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